Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: Results of a large, multicentre phase II study

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 1, 2004, Pages 75-81

  Morales, Serafín ^a   Lorenzo, Antonio ^b   Ramos, Manuel ^c   Ballesteros, Pedro ^d   Méndez, Miguel ^e   Almanza, Concepción ^f   Castellanos, Javier ^g   Moreno Nogueira, José Andrés ^h   Casal, Joaquín ⁱ   Lizón, José ^j   Oltra, Amparo ^k   Frau, Adolfo ^l   Machengs, Ignacio ^m   Galán, Antonio ⁿ   Belón, Joaquín ^o   Llorca, Cristina ^p  

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

^b HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

^c Centro Oncologico de Galicia   (Spain)

^d HOSPITAL LA INMACULADA   (Spain)

^e HOSPITAL DE MÓSTOLES   (Spain)

^f Servicio de Endocrinoloxía   (Spain)

^g HOSPITAL XERAL CÍES   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁱ HOSPITAL DO MEIXOEIRO   (Spain)

^j HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^k HOSPITAL VIRGEN DE LOS LIRIOS   (Spain)

^l HOSPITAL PROVINCIAL DE CASTELLÓN   (Spain)

^m HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

ⁿ HOSPITAL DE SAGUNTO   (Spain)

^o HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^p HOSPITAL GENERAL DE ELDA   (Spain)

more..

Author keywords

Docetaxel; Epirubicin; First line chemotherapy; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FARMORUBICINE; GRANULOCYTE COLONY STIMULATING FACTOR; HORMONE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE;

ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE CANCER; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CAUSE OF DEATH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLUID RETENTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERSENSITIVITY REACTION; HYPOXIA; INFECTION; LIVER METASTASIS; LUNG INFILTRATE; MAJOR CLINICAL STUDY; METASTASIS; MOTOR NEURON DISEASE; NAIL DISEASE; NAUSEA; NEUTROPENIA; PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SEPTIC SHOCK; SKIN CANCER; SKIN TOXICITY; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FRANCE; HUMANS; INFUSIONS, INTRAVENOUS; ITALY; MIDDLE AGED; NEOPLASM METASTASIS; TAXOIDS;

EID: 10744220317     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0690-0     Document Type: Article

References (37)

1. Airoldi M, Cattel L, Pedani F, Marchionatti S, Tagini V, Bumma C, Recalenda V (2001) Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. Breast Cancer Res Treat 70:185
2. Bastholt L, Dalmark M, Gjedde SB, Pfeiffer P, Pedersen D, Sandberg E, Kjaer M, Mouridsen HT, Rose C, Nielsen OS, Jakobsen P, Bentzen SM (1996) Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 14:1146
3. Bellot R, Robert J, Dieras V, Misset JL, Baille P, Bozec L, Vernillet L, Riva A, Azli N, Pouillart P (1998) Taxotere does not change the pharmacokinetic profile of doxorubicin (Dox) and doxorubicinol (Dx-ol) (abstract 853). Proc Am Soc Clin Oncol 17:221a
4. 2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group. Ann Oncol 8:155
5. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 17:2341
6. Crown J (1998) Evolution in the treatment of advanced breast cancer. Semin Oncol 25:12
7. Crown J (2001) Docetaxel: overview of an active drug for breast cancer. Oncologist 6:1
8. Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143
9. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16:3439
10. Friedrichs K, Holzel F, Janicke F (2002) Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report. Eur J Cancer 38:1730
11. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688
12. Hortobagyi GN (2002) The status of breast cancer management: challenges and opportunities. Breast Cancer Res Treat 75 [Suppl 1]:S61
13. Kardinal GG, Cole JT (1996) Chemotherapy of breast cancer. In: Perry MC (ed) The chemotherapy source book. Lippincott Williams & Wilkins, Philadelphia, p 1125
14. Kaufman PA (1999) Paclitaxel and anthracycline combination chemotherapy for metastatic breast cancer. Semin Oncol 26:39
15. Kouroussis C, Xydakis E, Potamianou A, Giannakakis T, Kakolyris S, Agelaki S, Sara E, Malamos N, Alexopoulos A, Mavroudis D, Samonis G, Papadouris S, Georgoulias V, Panagos G (1999) Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG). Ann Oncol 10:547
16. Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics. CA Cancer J Clin 49:8
17. Mavroudis D, Alexopoulos A, Ziras N, Malamos N, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Tsavaris N, Potamianou A, Rigatos G, Georgoulias V (2000) Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study. Ann Oncol 11:1249
18. Milla-Santos A, Milla L, Rallo L, Solano V (2001) High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer. Am J Clin Oncol 24:138
19. Misset JL, Dieras V, Gruia G, Bourgeois H, Cvitkovic E, Kalla S, Bozec L, Beuzeboc P, Jasmin C, Aussel JP, Riva A, Azli N, Pouillart P (1999) Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 10:553
20. Nabholtz JM, Riva A (2001) Taxane/anthracycline combinations: setting a new standard in breast cancer? Oncologist 6:5
21. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17:1413
22. Nabholtz JM, Smylie M, Mackey J, Au HJ, Tonkin K, Au R, Morrish D, Salter E (1999) Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer. Semin Oncol 26:47
23. Nabholtz JM, Tonkin K, Smylie M, Mackey J, Janowska-Wieczorek A (1999) Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting. Semin Oncol 26:10
24. Nabholtz JM, North S, Smylie M, Mackey J, Au HJ, Au R, Morrish D, Salter E, Tonkin K (2000) Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer. Semin Oncol 27:11
25. Nabholtz JM, Tonkin K, Smylie M, Au HJ, Lindsay MA, Mackey J (2000) Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? Expert Opin Pharmacother 1:187
26. Pagani O, Sessa C, Martinelli G, Crivellari D, Buonadonna A, Thurlimann B, Hess D, Borner M, Bauer J, Zampino G, Zimatore M, Graffeo R, Riva A, Goldhirsch A (1999) Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Ann Oncol 10:539
27. Pagani O, Sessa C, Nole F, Crivellari D, Lombardi D, Thurlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Zucchetti M, D'Incalci M, Goldhirsch A (2000) Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Ann Oncol 11:985
28. Raab G, Borquez D, Harstrick A, Wilke HJ, Actherrath W, Eiermann W, Seeber S (1998) Phase I study of docetaxel (D) in combination with epirubicin (E) as first-line chemotherapy (CT) in metastatic breast cancer (abstract 644). Proc Am Soc Clin Oncol 17:168a
29. Salminen E, Korpela J, Varpula M, Asola R, Varjo P, Pyrhonen S, Mali P, Hinkka S, Ekholm E (2002) Epirubicin/docetaxel regimen in progressive breast cancer - a phase II study. Anticancer Drugs 13:925
30. Schuller J, Czejka M, Kletzl H, Wirth M, Springer B, Kriwanek S, Terkola R, Schernthaner G (1998) Doxorubicin (DOX) and Taxotere (TXT): a pharmacokinetic study of the combination in advanced breast cancer (abstract 790). Proc Am Soc Clin Oncol 17:205a
31. Sparano JA, O'Neill A, Schaefer PL, Falkson CI, Wood WC (2000) Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol 18:2369
32. Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, Vandenberg TA, Delorme F, Muldal AM (1996) Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada - Clinical Trials Group. J Clin Oncol 14:422
33. Trudeau ME, Crump M, Latreille J, Pritchard K, Palmer M, Tu D, Shepherd L, Shear N, Shapiro L, Delorme F (1999) Escalating doses of docetaxel and epirubicin as first-line therapy for metastatic breast cancer. A phase I/II study of the National Cancer Institute of Canada - Clinical Trials Group (abstract 687). Proc Am Soc Clin Oncol 18:178a
34. Venturini M, Michelotti A, Papaldo P, Garrone O, Bergaglio M, Donati S, Lionetto R, Guelfi M, Sguotti C, Cognetti F, Rosso R (1998) First line epirubicin (EPI) and Taxotere (TXT) in advanced breast cancer: a phase I study (abstract 690). Proc Am Soc Clin Oncol 17:179a
35. Venturini M, Michelotti A, Papaldo P, Del Mastro L, Bergaglio M, Lionetto R, Lunardi G, Sguotti C, Frevola L, Donati S, Rosso R, Cognetti F (2001) Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. Ann Oncol 12:1097
36. Viens P, Roche H, Kerbrat P, Fumoleau P, Guastalla JP, Delozier T (2001) Epirubicin-docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study. Am J Clin Oncol 24:328
37. Wenzel C, Locker GJ, Schmidinger M, Rudas M, Taucher S, Gnant MF, Jakesz R, Steger GG (2002) Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel + granulocyte colony stimulating factor. Anticancer Drugs 13:67